Vaccination with live Leishmania major has been shown to yield effective immunization in humans; however, this has been discontinued because of problems associated with virulence of the available vaccine lines. To circumvent this, we tested the ability of a dhfr-ts-null mutant of L. major, obtained by gene targeting, to infect and then to vaccinate mice against challenge with virulent L. major. Survival and replication of dhfr-ts-in macrophages in vitro were dependent upon thymidine, with parasites differentiating into amastigotes prior to destruction. dhfr-ts-parasites per-
Protozoan parasites of the genus Leishmania reside within macrophages, where in humans they induce a spectrum of diseases ranging from mild cutaneous to lethal visceral forms. When infected with Leishmania, especially species causing cutaneous disease, most humans mount an effective response that resolves the infection and confers solid immunity to reinfection (1) (2) (3) (4) . This suggested that among the parasitic diseases of humans, Leishmania would be one for which a vaccine could be developed with relative ease. However, there is still no safe and effective vaccine.
In some areas individuals deliberately infect themselves with virulent Leishmania major on regions of the body where resultant scarring is hidden (a practice known as "leishmanization"; refs. 3 and 5) . This usually leads to solid immunity; however, infections induced in this manner can prove as troublesome as naturally acquired disease. These problems led many workers to attempt vaccination by attenuated/avirulent forms of Leishmania. For example, y-irradiated L. major elicit substantial protection in mice to challenge with virulent L. major (ref. 6 ; for review, see ref. 7) . Similar results have been obtained with attenuated Leishmania derived by long-term culture in vitro (8) (9) (10) (11) , selection for temperature sensitivity (12) , or chemical mutagenesis (9, 13, 14) . Unfortunately, the attenuating defect in these lines has not been defined, and they can revert toward virulence and/or persist for long periods of time (6, 15) . Persistence of asymptomatic Leishmania infections raises the risk of subsequent reactivation, especially in AIDS (16) (17) (18) (19) (20) (21) where leishmaniasis is an opportunistic infection. These problems led to current efforts to develop purified molecules as immunogens or to engineer their delivery with live vaccine vehicles such as Salmonella or bacillus CalmetteGuerin (BCG) (22, 23) . However, the use of a live Leishmania vaccine might still be superior if it could be made safe.
To thymidine at 10 jig/ml was added for dhfr-ts-). Metacyclic dhfr-ts-promastigotes were purified by using peanut agglutinin (28) and a freeze-thaw lysate was made (27) . BALB/c and BALB/c athymic nu/nu mice were obtained from the National Cancer Institute (Frederick, MD); CBA/T6 mice were obtained from The Jackson Laboratory. Subcutaneous injections were delivered at a shallow site in the hind footpad, i.v. inoculations were into the tail vein, and i.m. injections were into the large rear leg muscle mass. Lesion progression was followed by using a vernier caliper (27) . Macrophages were elicited with starch in the peritoneum of BALB/c mice, harvested, and infected with parasites, and their parasite burden was assessed as described (29) . The limiting dilution assay for enumerating parasites in infected mouse tissues was performed as described (17) . Lymph node cell proliferation assays were performed as described (14) . Osmotic pumps (14- (Fig. 1B) . To confirm that the destruction of dhfr-ts-arose specifically from the lack of DHFR-TS, we added thymidine (100 tLg/ml) to the medium, which restored both survival and replication (Fig.  1A) .
Inability In several experiments we attempted to rescue the dhfr-tsphenotype in vivo, by implanting osmotic pumps that delivered thymidine at the maximum tolerated dose for either 14 or 28 days. Small lesions (up to 0.25 mm) were obtained after infection with 108 dhfr-ts-(data not shown). The small size relative to infection with CC-1 ( Fig. 24 ) may be due to (i) the rapid clearance of thymidine from the bloodstream (32), (ii) difficulty in delivering thymidine to the Leishmania phagolysosomal compartment, and/or (iii) a need in vivo but not in vitro for reduced folates, beyond the capacity of the alternative pteridine reductase PTR1 (33) . Significantly, upon removal of the thymidine pumps, dhfr-ts-lesions regressed immediately and disappeared within 2 weeks (data not shown).
Finally, we tested whether dhfr-ts-would induce cutaneous lesions in BALB/c athymic nu/nu mice, which are severely immunocompromised and the most permissive host known for L. major. Cutaneous lesions did not occur for 220 days after infection with 108 dhfr-ts-(data not shown), the maximum observation period since nu/nu mice die prematurely.
dhfr-ts-Persist Briefly After Mouse Infection. The studies above addressed infectivity by the criterion of visible lesion development. Since Leishmania can persist in the absence of overt disease (16-21), we measured the number of viable dhfr-ts-parasites after infection. Susceptible BALB/c mice were injected s.c. in one hind footpad with 108 dhfr-tsparasites and, at various intervals, were sacrificed, and parasites were enumerated in the footpad and the draining lymph node. The dhfr-ts-parasites persisted for nearly 2 Macrophages infected with dhfr-ts-in the absence of thymidine for 24-48 hr were fixed and stained as described (29) . Arrowhead marks one of the many amastigote-stage dhfr-ts-evident in these preparations. days (Fig. 2B) . From the macrophage results (Fig. 1) , we infer that the persisting parasites were amastigotes.
Vaccinating BALB/c Mice with dhfr-ts-i.v. Induces Substantial Immunity to Virulent L. major. While the dhfr-ts-line persists briefly in mice, it does not cause disease. To test its ability to induce protective immunity, we vaccinated BALB/c mice with stationary-phase dhfr-ts-and challenged them 1 week later with 106 virulent L. major, delivered s.c. Vaccination i.v. induced high levels of immunity (Fig. 3A) , consistent with previous studies showing this to be the most effective route to induce immunity against L. major in mice (7, 8, 13) . The most striking results were achieved with intermediate doses of dhfr-ts-(105-106 parasites, Fig. 3B ). For example, animals vaccinated with 105 dhfr-ts-controlled lesion development for 277 days (Fig. 3A) . The basis for the dose dependency has not been studied but is interesting in light of the results of Bretscher et al. (34) who showed that administrating low doses of virulent L. major conferred protection to BALB/c and CBA mice.
With BALB/c mice, vaccination with purified metacyclic dhfr-ts-was no more effective than stationary-phase dhfr-ts-, and a metacyclic dhfr-ts-lysate did not confer protection (Fig.  3C ). Other workers have also reported that parasite lysates are ineffective (10, 35) . Similar results were obtained when mice were challenged 1 month after vaccination (data not shown). Vaccination by the s.c. route imparted minimal protection (Fig. 3C) .
There was a correlation between lesion size and parasite burden in vaccinated BALB/c mice ( Fig. 3C and Table 1 ). In mice vaccinated with stationary-phase dhfr-ts-, the parasite burden was reduced 158-fold at day 34 and 1900-fold at day 62 of infection (Table 1) .
Vaccinating CBA Mice with dhfr-ts-i.v., s.c., or i.m. Induces Substantial Immunity. We vaccinated resistant CBA mice with dhfr-ts-, as the disease progression in this strain more closely resembles that observed in human infections. In these experiments, we vaccinated with stationary-phase dhfr-ts-and challenged with virulent L. major after 1 week. Similar results were obtained after vaccination with purified metacyclics and challenge after 1 month (data not shown).
Like BALB/c mice, i.v. vaccination of CBA mice with dhfr-ts-was highly protective (Fig. 4A) . Unlike BALB/c mice, CBA mice were protected best by large doses of dhfr-ts-(108; Figs. 4A and 3B) . Significantly, vaccination of CBA mice with 108 dhfr-ts-by either the s.c. or i.m. routes was protective (Fig.  4 B and C) , although less so than by the i.v. route (Fig. 4A) 
DISCUSSION
Safety. dhfi-ts-was incapable of establishing a persistent infection or causing disease in the most susceptible strains of mice tested. This defect specifically arises from the lack of DHFR-TS, as shown by rescue of dhfr-ts-both in vitro and in vivo by thymidine supplementation. As for other intracellular pathogens such as Salmonella, the levels of thymidine available within the parasitophorous vacuole appear insufficient to permit propagation and pathogenesis. Even artificial continuous administration of massive subtoxic thymidine supplementation was only able to partially restore infectivity to dhfr-ts-, and lesions immediately regressed upon thymidine withdrawal. Given the tight physiological regulation of thymidine levels (32), it is highly unlikely that rescue could ever occur during natural infections.
Despite the block to propagation and pathogenesis, the low thymidine levels available to Leishmania in vivo are apparently sufficient to prevent or delay classic rapid thymine-less death. This follows because dhfr-ts-did not perish immediately in vivo but, instead, slowly declined over a period of months (complete removal of thymidine results in rapid death within a few days in vitro; ref. 24) . Thus, subtle interactions between dhfr-ts-and the host exist that promote limited persistence simultaneously with differentiation. Minimally, this should prolong the period of exposure to both live and dead parasite antigens, while differentiation of dhfr-ts-would deliver substantial quantities of amastigote antigens. These features would seem to be advantagenous to vaccination efforts and may perhaps be unique to dhfr-ts-knockouts, relative to other potential candidate attenuating loci that we have considered.
Potential Application of DHFR-TS as a Selective Marker in Vitro and in Vivo. Recently, workers studying prokaryotic pathogens developed powerful strategies for identifying stagespecific genes, based upon the rescue of avirulent auxotrophic pathogens (36, 37) . In Salmonella and Vibrio, this can be performed by rescue of thy-auxotrophs with constructs expressing thymidylate synthase under control of stage-specific promoters (37) . Our demonstration that dhfr-ts-knockouts are similarly avirulent suggests that expression of DHFR-TS under the control of appropriate Leishmania regulatory elements could be used in an analogous approach.
Vaccination. dhfr-ts-was found to be an effective vaccine line for immunizing against cutaneous leishmaniasis, whether delivered by the i.v., s.c., or i.m. routes (Figs. 3 and 4 Since it is now possible to introduce and express foreign proteins readily in Leishmania, one could further engineer the dhfr-ts-parasite to enlarge or improve its vaccination potential. Candidate proteins that might improve vaccination include immunodominant or protective antigens, lymphokines, or immunomodulatory substances such as those present in the saliva injected by the fly along with Leishmania (38) , and expression of several of these has been achieved (39) (40) (41) . Potentially, dhfr-ts-Leishmania could also be used as a platform for introduction of immunoprotective antigens relevant to other diseases.
Prospects for Vaccination of Humans with dhfr-ts-Leishmania. dhfr-ts-is totally avirulent (Figs. 1 and 2 ) and elicits protection in mice by routes that have traditionally been used to deliver other vaccines to humans (s.c. and i.m.). These findings and the success of past vaccination campaigns with live Leishmania cause us to be optimistic for the safety and efficacy of dhfr-ts: vaccination in humans. Since all DHFR-TS sequences have been eliminated, this mutation cannot revert and we have not recovered any second-site thy+ revertants thus far (unpublished data). Certainly these parasites should be much safer than the ones used in previous vaccinations with live virulent L. major, which were given to more than one million people (3) .
While our data argue that the dhfr-ts-parasite is safe, we have reported (42) that the neomycin phosphotransferase gene used here confers cross-resistance to paromomycin, a drug being used increasingly in antileishmanial chemotherapy. This raises the remote possibility that neomycin phosphotransferase genes introduced by vaccination campaigns could escape into virulent populations, depending upon the extent of sexual exchange in Leishmania, which has yet to be convincingly demonstrated. To this end, we have recently succeeded in generating marker-free dhfr-ts-deletion L. major, which in preliminary tests vaccinate as effectively as the dhfr-ts-line tested here (F.J.G.-F. and S.M.B., unpublished results).
Given the unchanging role of DHFR-TS in parasite metabolism, it is likely that dhfr-ts-knockouts in other Leishmania species may prove similarly safe and effective. While cutaneous leishmaniasis is rarely life-threatening, mucocutaneous leishmaniasis is more severe and disfiguring and visceral leishmaniasis caused by species of the Leishmania donovani complex is often fatal. The health risk posed by these Leishmania has justifiably precluded tests of live vaccine strains. dhfr-tsknockouts in viscerotropic species, perhaps in combination with further attenuating mutations, may permit exploration of this vaccination method against visceral leishmaniasis.
Note Added in Proof. Transfection of a functional DHFR-TS gene back into dhfr-ts-has recently been shown to restore infectivity to BALB/c mice.
